COMMUNIQUÉS West-GlobeNewswire

Leading Scientists Demonstrate How Seer’s Proteograph Product Suite Advances Cardiovascular and Neurodegenerative Research at US HUPO 2026
19/02/2026
Nathan Basisty, Sasha Singh, Bruce Wilcox, and Mozhgan Boroumand among scientific leaders presenting unique proteomics-enabled biological insights REDWOOD CITY, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. ( [...]
NovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board to Further Accelerate Global Biotech Platform
19/02/2026
Appointment is a positive endorsement of NovaBridge’s unique hub-and-spoke model and focus on creating shareholder value by accelerating the development of transformative medicines for patients around the world As a [...]
Ipsen S.A. publishes its 2025 Consolidated Financial Statements
19/02/2026
Ipsen S.A. publishes its 2025 Consolidated Financial Statements Attachment Ipsen_Consolidated financial statements 2025_GB
Philips publishes its Annual Report 2025
19/02/2026
February 19, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today published its Annual Report 2025. Philips’ Annual Report 2025 will be on the agenda of the [...]
Ipsen S.A. publie ses comptes consolidés 2025
19/02/2026
Ipsen S.A. publie ses comptes consolidés 2025 Pièce jointe Ipsen_Comptes Consolidés 2025_FR
Reacta Healthcare Appoints Richard Nagle as Chair of Board of Directors
19/02/2026
Pharma, Biotech and Medtech Sector Leader and Entrepreneur to Drive Further Growth and Strategic Expansion DEESIDE, United Kingdom, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Reacta Healthcare Ltd, a leading developer of food [...]
Q-Sera announces the first launch of blood collection tubes using its patented Rapclot technology in Japan, opening opportunities for additional global partnerships
19/02/2026
MELBOURNE, Australia , Feb. 19, 2026 (GLOBE NEWSWIRE) -- Q-Sera Pty Ltd, an Australian venture-backed company, today announced the first product launch of its patented evacuated blood collection technology, with the [...]
Valneva publie son chiffre d’affaires et sa trésorerie non audités pour l’exercice 2025 et fournit ses prévisions pour l’exercice 2026
19/02/2026
Chiffre d’affaires de 174,7millions d’euros en ligne avec les prévisions, dont 157,9 millions d’euros de ventes de vaccins Solide position de trésorerie de 109,7 millions d’euros à fin 2025 et flexibilité financière [...]
BioVersys and Partners’ Phase 2a Tuberculosis Trial Results Published in New England Journal of Medicine
19/02/2026
Data from Phase 2a study demonstrated the first clinical proof of concept for alpibectir in combination with ethionamide (AlpE) in the treatment of patients with tuberculosis. The results, published in the prestigious [...]
Valneva Reports Preliminary Unaudited 2025 Revenue and Cash and Provides 2026 Outlook
19/02/2026
Total Revenues of €174.7 million in line with guidance, including €157.9 million in product sales Strong year-end cash position of €109.7 million, with enhanced financial flexibility following successful debt [...]
argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026
19/02/2026
February 19, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that [...]
IBA and Shreeji sign multi‑site agreement for four cyclotrons to expand PET radiopharmaceutical manufacturing across India
19/02/2026
Louvain-la-Neuve, Belgium – 19 February 2026 – IBA (Ion Beam Applications S.A., EURONEXT) , the world leader in particle accelerator technology with a preeminent position in nuclear medicine, and Shreeji (Shreeji [...]
IBA et Shreeji signent un accord pour quatre cyclotrons afin d’étendre la production de radiopharmaceutiques TEP en Inde
19/02/2026
Louvain-la-Neuve, Belgium – 19 février 2026 – IBA (Ion Beam Applications S.A., EURONEXT) , le leader mondial des technologies d'accélérateurs de particules et acteur de premier plan en médecine nucléaire, et Shreeji ( [...]
Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants
19/02/2026
VICTORIA, British Columbia, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary [...]
Zealand Pharma Announces Financial Results for the Full Year 2025
19/02/2026
Company announcement – No. 1 / 2026 Zealand Pharma Announces Financial Results for the Full Year 2025 2025 marked a quantum leap for Zealand Pharma, with a transformative partnership for petrelintide, strong clinical [...]
Rapid Nutrition PLC – Strategic Outlook and Near-Term Execution Update
19/02/2026
Well-capitalised HealthTech group enters delivery phase across platform expansion, selective acquisitions and science-led product development LONDON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Rapid Nutrition PLC , a HealthTech [...]
ACTG Announces Publication of LATITUDE Findings in the New England Journal of Medicine
18/02/2026
Study Confirms Long-Acting Treatment is Effective among People Living with HIV Who Experience Challenges Taking Daily Oral Treatment CHAPEL HILL, N.C., Feb. 18, 2026 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials [...]
Nyxoah Announces the Signature of a Memorandum of Understanding with Sheikh Shakhbout Medical City Hospital to Improve OSA Therapy Management and Accelerate Access to Genio in the Middle East
18/02/2026
Nyxoah Announces the Signature of a Memorandum of Understanding with Sheikh Shakhbout Medical City Hospital to Improve OSA Therapy Management and Accelerate Access to Genio in the Middle East Mont-Saint-Guibert, Belgium [...]
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026
18/02/2026
REDWOOD CITY, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today [...]

Pages